Stockscreener 앱 받기
39.77
0.05%
0.02
시간 외 거래:
39.77
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.
CRNX (NASDAQ: CRNX) files Rule 144: 20,900-share exercise, prior 10b5-1 sales - Stock Titan
Insider Sales: CRNX (NASDAQ: CRNX) 4,434-share option sale; Knight 95,074 prior shares - Stock Titan
(CRNX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Fed Meeting: Is Crinetics Pharmaceuticals Inc stock a top performer YTD2026 Rallies & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Crinetics Pharmaceuticals Signs Independent Consultant Agreement with Jeff Knight – 8-K Filing Details and XBRL Information - Minichart
Crinetics Pharma chief dev officer sells $3.4m in stock By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals Insider Sold Shares Worth $3,415,036, According to a Recent SEC Filing - marketscreener.com
Crinetics (CRNX) COO exercises options and sells 85,163 shares under 10b5-1 - Stock Titan
Jeff Knight exits Crinetics (NASDAQ: CRNX) officer role, stays on under paid consulting deal - Stock Titan
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - Sahm
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Brazil ANVISA Filing For PALSONIFY - Sahm
Crinetics Pharmaceuticals to Report Q1 2026 Results on May 7 - National Today
Aug Retail: Whats the beta of Crinetics Pharmaceuticals Inc stock2026 Major Catalysts & Precise Buy Zone Identification - baoquankhu1.vn
Insider sale: CRNX (NASDAQ: CRNX) files Form 144 for 9,911 shares on 03/16/2026 - Stock Titan
Crinetics sets May 7 earnings call, business update after close - Stock Titan
Aug Shorts: Is Crinetics Pharmaceuticals Inc a stock for growth or value investors2026 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn
Future of Pituitary Cancer Market (2026-2033) | Precision - openPR.com
Risk Hedge: Is Crinetics Pharmaceuticals Inc exposed to currency risks2026 Market WrapUp & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Why Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint - Sahm
Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Price performance - Yahoo Finance Australia
Crinetics Pharmaceuticals Inc (6Z4.DU) stock price, news, quote and history - Yahoo Finance UK
Price-Driven Insight from (CRNX) for Rule-Based Strategy - Stock Traders Daily
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More - AOL.com
Crinetics Pharmaceuticals Director Sells Shares - intellectia.ai
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CRNX PE Ratio & Valuation, Is CRNX Overvalued - Intellectia AI
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharma Director Stock SaleMarch 2026 Transaction DetailsNews and Statistics - IndexBox
Crinetics Pharma COO to step down - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Crinetics submits application for acromegaly drug in Brazil By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify (Paltusotine) in Acromegaly - Bitget
Vanguard disaggregates holdings; Crinetics (CRNX) parent reports 0 shares - Stock Titan
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly - The Manila Times
Crinetics submits application for acromegaly drug in Brazil - Investing.com
Crinetics Pharmaceuticals Announces Submission of Marketing - globenewswire.com
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026 - MarketScreener
Crinetics Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details, Stock Info, and Compliance Data (March 2026) - Minichart
Crinetics Pharmaceuticals chief development and operating officer to resign By Investing.com - Investing.com South Africa
2.69%
0.25%
자본화:
|
볼륨(24시간):